Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis

about

Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis

Item

http://www.wikidata.org/entity/Q36829883

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Balanced control of both hyper ...... w treatment paradigm in sepsis

@en

type

Item

label

Balanced control of both hyper ...... w treatment paradigm in sepsis

@en

prefLabel

Balanced control of both hyper ...... w treatment paradigm in sepsis

@en

P1476

Balanced control of both hyper ...... w treatment paradigm in sepsis

@en

P2093

Ioanna Dimopoulou

http://www.w3.org/2001/XMLSchema#string

Josef Meletiadis

http://www.w3.org/2001/XMLSchema#string

Konstantinos Gkirkas

http://www.w3.org/2001/XMLSchema#string

Spiros Chondropoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

The pathophysiology and treatment of sepsis

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.

Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism.

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

Balance of inflammatory cytokines related to severity and mortality of murine sepsis.

Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients.

PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction.

P304

E312-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JTD.2016.03.47

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P Tsirigotis

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27162689

http://www.w3.org/2001/XMLSchema#string

P921

sepsis

P932

4842841

http://www.w3.org/2001/XMLSchema#string